Browsing Tag
Oncology
318 posts
Brooklyn Immuno Therapeutics acquires IRX Therapeutics’ assets for cytokine-based cancer therapy
Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition…
Seattle Genetics’ Adcetris receives FDA approval for peripheral T-cell lymphoma
Seattle Genetics’ Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell…
Fresenius Kabi launches generic Arsenic Trioxide Injection in US to enhance oncology treatment options
German health care company Fresenius Kabi has announced the US launch of its new generic drug, Arsenic Trioxide…
Pfizer’s Lorbrena receives FDA approval for advanced lung cancer treatment
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA)…
Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its…
Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1…
Five Prime Therapeutics and Zai Lab start Phase 3 study of bemarituzumab for advanced gastric cancer
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab…
Trovagene’s Onvansertib-decitabine combination trial shows promising results
Trovagene, a California-based cancer research company, has announced the successful completion of the second dosing cohort in its…
MedGenome study suggests cancer vaccine approach for treating Lynch Syndrome
Indian genomics research and diagnostics startup MedGenome recently unveiled promising results from a study on Lynch Syndrome, suggesting…
Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion
German pharmaceutical powerhouse Boehringer Ingelheim has acquired Austria-based oncolytic virus developer ViraTherapeutics for €210 million, cementing its strategic…